Gsa Capital Partners LLP Arvinas, Inc. Transaction History

Gsa Capital Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$21.73 - $31.43 $296,592 - $428,988	13,649 New	13,649 $338,000
Q4 2021 Feb 14, 2022	SELL	$65.85 - $96.21 $518,568 - $757,653	-7,875 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$73.2 - $107.87 $234,093 - $344,968	-3,198 Reduced 28.88%	7,875 $647,000
Q2 2021 Aug 05, 2021	BUY	$60.45 - $84.26 $258,846 - $360,801	4,282 Added 63.05%	11,073 $853,000
Q1 2021 May 10, 2021	SELL	$58.19 - $91.37 $179,050 - $281,145	-3,077 Reduced 31.18%	6,791 $449,000
Q4 2020 Feb 03, 2021	SELL	$20.19 - $84.93 $22,814 - $95,970	-1,130 Reduced 10.27%	9,868 $838,000
Q3 2020 Nov 06, 2020	BUY	$22.99 - $36.34 $81,154 - $128,280	3,530 Added 47.27%	10,998 $260,000
Q2 2020 Aug 11, 2020	BUY	$29.88 - $56.74 $223,143 - $423,734	7,468 New	7,468 $250,000

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $404M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.